Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI and big data could slash radiotherapy side effects in prostate cancer

NCT ID NCT06714630

Knowledge-focused Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study explores whether artificial intelligence, combined with large-scale healthcare records, can help personalize radiotherapy for prostate cancer. By analyzing data from 15,000 patients, researchers aim to find ways to reduce damage to healthy tissue without compromising tumor control. The goal is to develop a method that could be used routinely in the NHS to improve quality of life for cancer survivors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artificial intelligence analysis of linked healthcare records to personalize radiotherapy
What this could lead to
If successful, this could enable personalized radiotherapy for prostate cancer, reducing damage to healthy tissue while maintaining cure rates, and potentially be rolled out across the NHS.
What could go wrong
This is an observational study using historical data, so it cannot prove cause and effect. The results may not apply to all patients or future treatments, and the AI models may not be accurate enough for clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 15,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study requires no new data to be acquired relying solely on data collected on previously treated prostate cancer patients.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * External beam radiotherapy delivered by a linear accelerator * Prostate Specific Antigen (PSA) recorded at regular intervals after radiotherapy * Minimum of 10 year survival post-radiotherapy * Diagnostic Computerised Tomography (CT) acquired * Radiotherapy planning CT acquired * Radiotherapy treatment planning data available * Corresponding healthcare data available to infer toxicity events (ref previous work by Lemanska et al) Exclusion Criteria: * Incomplete course of radiotherapy * No PSA data * No follow-up corresponding healthcare data available * No imaging data available

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Edinburgh

    RECRUITING

    Edinburgh, Lothian, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.